NovelMed's Ruxoprubart Achieves 100% Transfusion Independence in PNH Phase II Trial, Gains Regulatory Clearance for Subcutaneous Dosing
Key Insights
NovelMed Therapeutics (search) reported positive Phase II results for Ruxoprubart in treatment-naïve PNH (search) patients, achieving 100% transfusion independence and hemoglobin improvements of 1.5-2.7 g/dL during weekly dosing.
The company received regulatory clearance to initiate Phase II trials for subcutaneous administration, enabling weekly self-injection at home and reducing patient burden from IV infusions.
Ruxoprubart's precision targeting of activated Bb (search) fragment provides selective alternative pathway inhibition while preserving classical pathway function for infection protection.
NovelMed Therapeutics (search) has announced two significant milestones for its investigational therapy Ruxoprubart (NM8074) in treating paroxysmal nocturnal hemoglobinuria (search) (PNH (search)), including positive Phase II monotherapy results and regulatory clearance for subcutaneous administration. The clinical-stage biopharmaceutical company reported that its intravenous Phase II study in treatment-naïve PNH patients met all efficacy endpoints while demonstrating an exceptional safety profile.
Phase II Monotherapy Results Demonstrate Clinical Efficacy
The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH (search) patients, achieving several key clinical outcomes. Hemoglobin levels increased by 1.5-2.7 g/dL, with an average rise of approximately 2.13 g/dL during weekly dosing, reflecting meaningful correction from the severely depressed baseline common in untreated PNH patients.
Most notably, 100% of patients achieved complete transfusion independence throughout the weekly dosing period, demonstrating effective control of hemolysis and clinically meaningful correction of anemia. PNH (search) red blood cell populations expanded to up to 94% of their maximum level, consistent with near-complete suppression of ongoing complement-mediated hemolysis.
"These milestones validate both our clinical progress and our development strategy," said Dr. Rekha Bansal, Chief Executive Officer of NovelMed. "Regulatory clearance of the SC route represents the next logical step toward a patient-friendly treatment option, while our monotherapy data demonstrate the strong, consistent efficacy and tolerability of targeting Bb (search)."
Subcutaneous Administration Cleared for Development
The regulatory agency has cleared the subcutaneous route of administration, enabling a planned weekly self-injection regimen at home. This approach is expected to reduce patient and caregiver burden by eliminating the need for IV infusions in a clinical setting. While SC trials are planned, they have not yet been initiated.
Lactate dehydrogenase (LDH) levels were significantly reduced, reflecting biochemical control of intravascular hemolysis. Patient-reported outcomes, including the Functional Assessment of Chronic Illness Therapy (FACIT) and the European Organization for Research and Treatment of Cancer (EORTC) questionnaires, showed meaningful improvements across fatigue, pain, and overall functional capacity.
Precision Targeting Mechanism Offers Differentiated Approach
Ruxoprubart is a first-in-class monoclonal antibody engineered for precision targeting of Bb (search), the proteolytically activated catalytic fragment generated upon alternative pathway activation. By binding Bb rather than native Factor B (search), Ruxoprubart delivers precise alternative pathway-selective inhibition while preserving the classical pathway, which remains essential for protecting patients from infections.
"Ruxoprubart has proven its potential as a definitive monotherapy, delivering exceptional efficacy without compromise," said Alex Kumar, Chief Strategy Advisor. "Coupled with FDA Orphan Drug Designation status and regulatory clearance for SC dosing, we have a clear, accelerated path forward."
The therapy was well-tolerated with no drug-related adverse events or serious adverse events observed during the Phase II study. Ruxoprubart holds U.S. FDA Orphan Drug Designation for PNH (search), highlighting its potential to address this rare and life-threatening condition.
Competitive Positioning in PNH Treatment Landscape
The current PNH (search) treatment landscape includes several complement inhibitors with different mechanisms of action. Soliris and Ultomiris from AstraZeneca target C5 (search) as distal blockers but fail to prevent C3b deposition, leading to persistent anemia. Empaveli from Apellis targets C3 (search) as a proximal blocker, providing broad inhibition but impacting overall complement surveillance. Novartis's Fabhalta targets native Factor B (search) but lacks precision by targeting the native protein rather than the activated fragment. AstraZeneca's Voydeya targets Factor D (search) but is approved only as an add-on therapy to C5 inhibitors.
"The Phase II intravenous results demonstrate a clinical efficacy and safety profile that aligns well with FDA expectations for monotherapy development in PNH (search)," said Robert Bard. "With the SC route now cleared for evaluation under our Phase II program, we are advancing along a well-defined regulatory path."
Strategic Partnership Opportunity
Following the achievement of 100% transfusion avoidance in its Phase II monotherapy study and regulatory clearance for subcutaneous administration, NovelMed is actively pursuing a strategic partnership to propel Ruxoprubart through late-stage global development. The company seeks a partner with extensive clinical and commercial expertise to accelerate the regulatory path towards approval and support the global launch of this patient-friendly, self-administered therapy.
PNH (search) is a rare, acquired, and life-threatening hematologic disorder caused by a somatic mutation in the PIGA gene, resulting in deficiency of GPI-anchored complement regulatory proteins CD55 and CD59. Without these protective proteins, red blood cells are highly vulnerable to persistent attack by the alternative pathway of the complement system, leading to chronic intravascular and extravascular hemolysis that manifests as severe anemia, elevated LDH levels, and increased risk of thrombosis and renal impairment.